State of Pre-Seed: 2025 in review

Pre-seed startup funding in 2025 exhibited a concentration of capital, with fewer overall instruments issued but some companies raising massive amounts.

State of Pre-Seed: 2025 in review

Introduction

2025’s a wrap, so we crunched the numbers to bring you our definitive breakdown of the year in pre-seed startup funding. Over the course of the full year, U.S.-based startups on Carta raised $10.4 billion across 50,316 SAFEs and convertible notes. 

Compared to 2024, that’s a 1% decline in total cash invested—not  a significant difference—but a 13% decline in the count of instruments. As we also saw on the priced equity side of fundraising, venture capital grew increasingly concentrated in 2025. 

The post-money SAFE with a valuation cap but no discount continues to be the standard pre-seed instrument. In 2025, median val caps on post-money SAFEs hovered around $10 million for rounds in the $250,000 to $1 million range and $15 million for rounds in the $1 million to $2.5 million range.

Continue reading for detailed charts and data on pre-seed investment volume, common deal terms, industry trends, top metro areas, and more.

2025 in review

  • Concentration of capital: 11,672 SAFEs and convertible notes were issued in Q4 2025, the lowest we’ve seen in recent years. However, those instruments represented $2.62 billion in investments, which is similar to the last several quarters.

  • The popularity of pre-priced funding: Founders are raising larger sums of money on convertible instruments before switching to priced equity. In 2025, the majority of early-stage rounds under $4 million were completed using SAFEs or convertible notes. 

  • SAFE valuation caps rise: In 2025, val caps on SAFEs increased across deal sizes, while caps on convertible notes experienced greater fluctuation. Also, convertible notes tend to have lower val caps than SAFEs.

  • Founders building in atoms: While SaaS remains the largest startup industry, hardware and biotech/pharma finished 2025 as the second and third largest by total cash raised. This is a noticeable difference from 2024, when hardware was third and biotech/pharma was fifth.

image30
image20
Data Minute Newsletter
Weekly data insights
One compelling chart per week from across Carta's 50,000+ startups and VC funds.